{
    "content": {
        "Document": [
            {
                "metadata": "（1）",
                "page_content": "Suspected Mpox Pathway for Patients self-presenting at Emergency \nDepartments\nDoes the patient have clinical signs and symptoms of being a   \nsuspected case?\n•\nA prodrome where there is known prior contact with a confirmed \nor suspected Mpox case in the last 21 days before symptom \nonset, or\n•\nAn Mpox compatible rash anywhere on the skin, mucosae or \nsymptoms of proctitis and at least one of the following in the 21 \ndays before symptom onset – \n•\nRecent new sexual partner\n•\nContact with known or suspected case of Mpox\n•\nA travel history to a country where Mpox is currently \ncommon\n•\nLink to infected animal or meat\n(N.B. If a rash is highly suggestive of Mpox, but a risk factor cannot be identified \nliaise with local infection specialist/microbiologist as to whether to consider Mpox \ntesting alongside the more common differential diagnosis)\nIsolate as per local pathways and clinically assess in line with National \nInfection Prevention & Control measures for clinically suspected and \nconfirmed cases of Mpox in healthcare settings\nConsider alternative diagnosis, \nseeking advice as required as \npart of normal clinical pathways. \nLiaise with local infection \nspecialists/microbiology if \nclinical suspicion remains to \nagree next steps – including  \nassessment for conditions such \nas malaria which could also \ncause illness in a returning \ntraveller\nNO\nYES\nLiaison with local infection specialist/Microbiology to discuss next steps, \nbegin symptomatic treatment and ensure isolation and appropriate PPE is \nmaintained throughout.\nLocal Infection Specialist/Microbiology to \ndiscuss risk assessment with Imported Fever \nService \n(0844 778 8990)\nLinks & Guidance\nMpox: guidance on when to suspect a case of Mpox\nClade 1 Mpox – affected countries list\nNational Infection Prevention & Control Manual (NIPCM) \nAddendum on HCID PPE\nPreparedness Actions\n•\nProviders to ensure that all clinical services are aware of the public health messaging and \nthat a differential diagnosis of Mpox should be considered in any patient that meets the \noperational case definition\n•\nProviders should review current IPC plans, PPE availability, waste management and staff \ntraining to ensure that arrangements are in place to safely assess and treat patients \npresenting with suspected Mpox\n•\nProviders should review existing plans and clinical pathways ensuring that staff are aware of \nthe arrangements for isolation, clinical management, specialist infection advice,  PPE and \nassociated infection control measures\nEmergency Department Mpox pathway checklist – \nprobable or possible cases\nHave you isolated the patient?\nHave you got access to the appropriate PPE (including donning & doffing procedures) to \nundertake a clinical assessment?\nSpeak to your Local Infection Specialist/Microbiologist for advice.\nContact with the Imported Fever Service should be via your local infection specialist ONLY\nNotify the relevant people in your department as per local pathways and agree clinical \nmanagement plan whilst awaiting test results\nTick\nIs there a high index of suspicion that this patient is a suspected Mpox \ncase?\nNO\nYES"
            },
            {
                "metadata": "（2）",
                "page_content": "Suspected Mpox Pathway for Patients referred to ED for clinical assessment and \ntesting by a Health Care Professional\nPatient has been identified as a suspected case of Mpox by a Health Care \nProfessional (including designated medical contacts for Returning Workers)\nHCP should contact ED to agree arrangements for transfer (e.g. likely time of arrival, arrival point, \nwhat to do on arrival, including phone number to notify of arrival)\nAssessment indicates patient is clinically \nstable and can transport themselves to attend \nED via their own transport, whilst maintaining \nisolation\nAssessment indicates patient is clinically \nunwell and should be transported by \nambulance, or is unable to self-transfer whilst \nmaintaining isolation\nHCP to contact regional ambulance service to \narrange transfer, clearly stating the patient is \na suspected Mpox case\nPatient to be managed as per local pathways and in line with Suspected Mpox Pathway for Patients \nself-presenting at Emergency Departments\nConfirm with patient arrangements for \ntransfer – \n•\nMaintain isolation\n•\nWhere to present\n•\nWho to contact upon arrival\nHCP Referral Mpox pathway checklist – probable or \npossible cases\nHave you isolated the patient?\nHave you assessed the patient's ability to self-transfer?\nHave you confirmed transfer/arrival arrangements with the receiving department?\nHave you confirmed arrangements with the patient, including a phone number to contact \nupon arrival\nTick\nLinks & Guidance\nPreparedness Actions\n•\nProviders to ensure that all clinical services are aware of the public health messaging and \nthat a differential diagnosis of Mpox should be considered in any patient that meets the \noperational case definition\n•\nProviders should review current IPC plans, PPE availability, waste management and staff \ntraining to ensure that arrangements are in place to safely assess and treat patients \npresenting with suspected Mpox\n•\nProviders should review existing plans and clinical pathways ensuring that staff are aware of \nthe arrangements for isolation, clinical management, specialist infection advice,  PPE and \nassociated infection control measures\nMpox: guidance on when to suspect a case of Mpox\nClade 1 Mpox – affected countries list\nNational Infection Prevention & Control Manual (NIPCM) \nAddendum on HCID PPE"
            },
            {
                "metadata": "（3）",
                "page_content": "Suspected Mpox Pathway for Patients who contact health services by phone or \npresent at a community-based setting\nPatient has been identified as requiring a clinical assessment to determine \nif they are a suspected case\nInitial assessment of patient to determine whether they are clinically stable or require immediate \nintervention, in community/outpatient settings (e.g. WIC and community pharmacies) \nPatients should be isolated/socially distanced and a virtual assessment should take place (e.g. by \nphone). Staff should not physically assess the patient without PPE\nAssessment indicates patient is clinically \nstable and can remain at home (or return \nhome via their own transport) whilst \nmaintaining isolation\nAssessment indicates patient is clinically \nunwell and should be transported by \nambulance, or is unable to self-transfer whilst \nmaintaining isolation\nAdvise the patient to dial 999 if urgent, or \ncontact regional ambulance service to arrange \ntransfer, clearly stating the patient is a \nsuspected Mpox case\nPatient should be advised to return home, \nmaintain isolation and contact 111\nCommunity based Mpox pathway checklist – \nprobable or possible cases\nWhere possible isolate/socially distance from the patient\nHave you assessed the patient's ability to self-transfer (maintaining self-isolation)?\nSeek advice from local Infection Prevention & Control as required (e.g. cleaning \nrequirements)\nLocal IPC Guidance \ncontact:\nTick\n111 pathway implemented\nEmergency Department Pathway implemented\nLinks & Guidance\nPreparedness Actions\n•\nProviders to ensure that all clinical services are aware of the public health messaging and \nthat a differential diagnosis of Mpox should be considered in any patient that meets the \noperational case definition\n•\nProviders should review current IPC plans, PPE availability, waste management and staff \ntraining to ensure that arrangements are in place to safely assess and treat patients \npresenting with suspected Mpox\n•\nProviders should review existing plans and clinical pathways ensuring that staff are aware of \nthe arrangements for isolation, clinical management, specialist infection advice,  PPE and \nassociated infection control measures\nMpox: guidance on when to suspect a case of Mpox\nClade 1 Mpox – affected countries list\nNational Infection Prevention & Control Manual (NIPCM) \nAddendum on HCID PPE"
            },
            {
                "metadata": "（4）",
                "page_content": "Links & Guidance\nPreparedness Actions\nSuspected Mpox Pathway for Patients self-presenting in Primary Care\nConsider alternative diagnosis, \nseeking advice as required as \npart of normal clinical pathways\nLiaise with local infection \nspecialists/microbiology if \nclinical suspicion remains to \nagree next steps – including  \nassessment for conditions such \nas malaria which could also \ncause illness in a returning \ntraveller\nNO\nYES\nNO\nIsolate the patient in a treatment room with access to a phone and \nundertake a clinical assessment of the patient\n•\nWhere appropriate PPE is available this can be done in person, where \nappropriate PPE is not available this should be done virtually\nWhere suspected cases present in primary care, General Practitioners should \nisolate the patient in a single room and contact their local infection service for \nadvice, including immediate precautions in the setting – clinical staff should \nwear face fit tested FFP3 masks, eye protection, long-sleeved fluid resistant \ngowns and gloves to provide care if immediately required.\nPatient presents to primary care and is identified as at risk of possible Mpox\nFollow the suspected case of Mpox identified by a Health \nCare Professional Pathway\n•\nProviders to ensure that all clinical services are aware of the public health messaging and that a \ndifferential diagnosis of Mpox should be considered in any patient that meets the operational case \ndefinition\n•\nProviders should review current IPC plans, PPE availability, waste management and staff training to \nensure that arrangements are in place to safely assess and treat patients presenting with suspected \nMpox – this should include identifying a suitable room and access & egress arrangements\n•\nProviders should review existing plans and clinical pathways ensuring that staff are aware of the \narrangements for isolation, clinical management, specialist infection advice,  PPE and associated \ninfection control measures\nHCP Referral Clade 1 Mpox pathway checklist – \nprobable or possible cases\nHave you isolated the patient?\nHave you assessed the patient's ability to self-transfer?\nHave you confirmed transfer/arrival arrangements with the receiving department?\nHave you confirmed arrangements with the patient, including a phone number to contact \nupon arrival\nTick\nSeek advice from local Infection Prevention & Control as required (including cleaning)\nLocal IPC Guidance contact:\nYES\nDoes the patient have clinical signs and symptoms of being a   \nsuspected case?\n•\nA prodrome where there is known prior contact with a confirmed \nor suspected Mpox case in the last 21 days before symptom \nonset, or\n•\nAn Mpox compatible rash anywhere on the skin, mucosae or \nsymptoms of proctitis and at least one of the following in the 21 \ndays before symptom onset – \n•\nRecent new sexual partner\n•\nContact with known or suspected case of Mpox\n•\nA travel history to a country where Mpox is currently \ncommon\n•\nLink to infected animal or meat\n(N.B. If a rash is highly suggestive of Mpox, but a risk factor cannot be identified \nliaise with local infection specialist/microbiologist as to whether to consider Mpox \ntesting alongside the more common differential diagnosis)\nYES\nMpox: guidance on when to suspect a case of Mpox\nClade 1 Mpox – affected countries list\nNational Infection Prevention & Control Manual (NIPCM) \nAddendum on HCID PPE"
            }
        ]
    },
    "time": "2024_10_25",
    "source": "BMJ:Mpox pathway action cards",
    "link": "https://www.england.nhs.uk/wp-content/uploads/2024/09/mpox-pathway-action-cards-v2.3.pdf"
}